证券日报网讯12月19日，福安药业（300194）发布公告称，公司将于2026年1月6日召开2026年第一次临 时股东会。 ...

（文章来源：证券日报） 证券日报网讯 12月19日，福安药业发布公告称，公司第六届董事会第五次会议审议通过《关于变更 2025年度审计机构的议案》《关于召开2026年第一次临时股东会的议案》。 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-047 关于变更公司 2025 年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、拟变更会计师事务所名称：中兴华会计师事务所（特殊普通合伙）（以下 简称"中兴华会计师事务所"）；原聘任会计师事务所名称：永拓会计师事务所 （特殊普通合伙）（以下简称"永拓所"）。 2、变更会计师事务所的原因：鉴于永拓所被中国证券监督管理委员会江苏 监管局行政处罚，被禁止从事证券服务业务，无法继续完成公司 2025 年度财务 报告和内部控制审计工作。为保证公司 2025 年度审计工作顺利进行，结合公司 业务发展和审计需求等实际情况，福安药业（集团）股份有限公司（以下简称"公 司"）拟变更 2025 年度财务报告及内部控制审计机构为中兴华会计师事务所。 3、公司已就拟变更会计师事务所的相关事宜与前后任会计师事务所进行了 沟通，前后任会计师事务所已明确知悉本次拟变更事项并确认无异议。公司董事 会、审计委员会对本次拟变更审计机构的事项均不存在异议。 4、本次变更会计师事务所事项符合财政部 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-046 福安药业（集团）股份有限公司 关于召开2026年第一次临时股东会的通知 根据《公司法》和《公司章程》的有关规定，经福安药业（集团）股份有限 公司（以下简称"公司"）第六届董事会第五次会议审议通过，决定于 2026 年 1 月 6 日召开公司 2026 年第一次临时股东会，现将会议有关事项通知如下： 一、本次股东会召开的基本情况 （一）股东会届次：2026 年第一次临时股东会。 （二）股东会的召集人：公司董事会 （三）本次会议的召集、召开符合《中华人民共和国公司法》、《深圳证券交 易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 （四）会议时间： （1）现场会议时间：2026 年 1 月 6 日（星期二）下午 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026年1月6日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为20 ...

证券代码：300194 证券简称：福安药业 公告编号：2025-045 第六届董事会第五次会议决议公告 （现场表决和通讯表决相结合方式） 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称 "公司"）第六届董事会第五 次会议于 2025 年 12 月 19 日在公司会议室召开。应到董事 9 名，实到董事 9 名。本次会议采用现场表决和通讯表决结合方式召开，其中现场参加会议董事 6 名，通讯表决参加会议董事 3 名。会议通知已于 2025 年 12 月 13 日以电话、传 真、邮件等方式发出。本次会议的召集、召开与表决程序符合《公司法》、公司 章程的规定。 本次会议由董事长汪天祥先生主持，经与会董事认真审议，本次会议审议通 过了相关议案，并作出如下决议： 一、审议通过《关于变更 2025 年度审计机构的议案》 公司拟变更中兴华会计师事务所（特殊普通合伙）为公司 2025 年财务报告 及内部控制审计机构，聘期一年。审计费用 136 万元（其中财务报告审计费用 120 万元，内部控制审计费用 16 万元）。详细内容请见与本决议 ...

（记者 贾运可） 截至发稿，福安药业市值为56亿元。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ 每经AI快讯，福安药业（SZ 300194，收盘价：4.7元）12月19日晚间发布公告称，公司第六届第五次董 事会会议于2025年12月19日在公司会议室召开。会议审议了《关于变更2025年度审计机构的议案》等文 件。 2025年1至6月份，福安药业的营业收入构成为：医药行业占比100.0%。 ...

（文章来源：证券日报） 证券日报网讯 12月16日，福安药业在互动平台回答投资者提问时表示，截至12月10日，公司股东户数 为38855户。 ...

Core Viewpoint - The A-share market's industrial hemp concept stocks have shown strong performance, with notable gains in several companies, driven by potential regulatory changes in the U.S. regarding cannabis classification [1][2]. Company Performance - Shunhao Co., Ltd. (002565) reached a limit-up with a 10% increase, total market value at 16.9 billion [2]. - Fuan Pharmaceutical (300194) rose by 4.91%, with a market cap of 5.592 billion [2]. - Blue Sky Technology (300487) increased by 4.85%, total market value at 29.1 billion [2]. - Jinying Co., Ltd. (600232) saw a 4.10% rise, with a market cap of 2.593 billion [2]. - Chengyitong (300430) grew by 3.82%, total market value at 5.117 billion [2]. - Yongji Co., Ltd. (603058) increased by 3.44%, with a market cap of 3.740 billion [2]. - Morning Light Biology (300138) rose by 3.19%, total market value at 6.097 billion [2]. Regulatory Impact - Reports indicate that former President Trump is expected to instruct the government to reclassify cannabis as a lower-risk substance, which could represent a significant shift in U.S. cannabis policy [1][2]. - Discussions have taken place between Trump and industry executives, as well as health officials, regarding this potential reclassification [2]. - The reclassification could facilitate easier buying and selling of cannabis, addressing tax burdens and banking service obstacles for cannabis businesses [2].

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

Core Viewpoint - Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Hubei Renmin Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for the injectable drug, Isavuconazole Sulfate, which is indicated for the treatment of invasive aspergillosis and mucormycosis in adult patients [1] Group 1 - The drug Isavuconazole Sulfate is specifically designed for treating serious fungal infections [1] - The approval of this drug expands the company's product portfolio in the antifungal treatment segment [1] - This development may enhance the company's market position in the pharmaceutical industry, particularly in the area of critical care medications [1]